Humanigen (HGENQ) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 09, 2020
Document and Entity Information
Entity Registrant Name	HUMANIGEN, INC
Entity Central Index Key	0001293310
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		51,616,508
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35798
Document Quarterly Report	true
Document Transition Report	false
Entity Shell Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 91,431	$ 143
Prepaid expenses and other current assets	618	309
Total current assets	92,049	452
Intangible assets	20
Restricted cash	70	71
Total assets	92,139	523
Current liabilities:
Accounts payable	8,743	5,046
Accrued expenses	6,126	3,308
Bridge Notes		2,113
Convertible notes - current		2,033
Notes payable to vendors		1,094
Total current liabilities	14,869	13,594
Convertible notes - non current		1,247
Total liabilities	14,869	14,841
Stockholders' equity (deficit):
Common stock, $0.001 par value: 225,000,000 shares authorized at September 30, 2020 and December 31, 2019; 51,616,508 and 22,806,890 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	52	22
Additional paid-in capital	419,353	270,555
Accumulated deficit	(342,135)	(284,895)
Total stockholders' equity (deficit)	77,270	(14,318)
Total liabilities and stockholders' equity (deficit)	$ 92,139	$ 523

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Sep. 11, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares authorized	225,000,000	225,000,000	225,000,000
Common stock, shares issued	51,616,508		22,806,890
Common stock, shares outstanding	51,616,508		22,806,890

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 22,416	$ 549	$ 44,218	$ 2,142
Selling, general and administrative	8,331	1,497	11,685	5,122
Total operating expenses	30,747	2,046	55,903	7,264
Loss from operations	(30,747)	(2,046)	(55,903)	(7,264)
Other expense:
Interest expense	(3)	(343)	(1,336)	(1,003)
Other expense, net	(1)		(1)	(1)
Net loss	$ (30,751)	$ (2,389)	$ (57,240)	$ (8,268)
Basic and diluted net loss per common share	$ (0.71)	$ (0.11)	$ (1.79)	$ (0.37)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share	43,490,071	22,553,322	32,041,790	22,260,783

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net loss	$ (57,240)	$ (8,268)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense	1,634	1,877
Issuance of common stock for payment of compensation	78	120
Issuance of common stock in exchange for services	212	71
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(309)	119
Accounts payable	3,697	1,076
Accrued Expenses	5,770	1,553
Net cash used in operating activities	(46,158)	(3,452)
Investing activities:
Purchase of intangible assets	(20)
Net cash used in investing activities	(20)
Financing activities:
Net proceeds from issuance of common stock	139,760
Proceeds from exercise of stock options	572	325
Proceeds from exercise of warrants	10
Net proceeds from issuance of convertible notes	467	1,275
Net proceeds from issuance of PPP loan	83
Net proceeds from issuance of bridge notes	350	1,700
Payments on PPP loan	(83)
Payments on bridge notes	(2,400)
Payments on convertible notes	(518)
Payments on notes payable to vendors	(776)	(505)
Net cash provided by financing activities	137,465	2,795
Net increase (decrease) in cash, cash equivalents and restricted cash	91,287	(657)
Cash, cash equivalents and restricted cash, beginning of period	214	885
Cash, cash equivalents and restricted cash, end of period	91,501	228
Supplemental cash flow disclosure:
Cash paid for interest	671	8
Supplemental disclosure of non-cash investing and financing activities:
Conversion of notes payable and related accrued interest and fees to common stock	4,316	981
Beneficial conversion feature of convertible notes		143
Issuance of stock options in lieu of cash compensation	180	195
Issuance of warrants for services	$ 2,066

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balances at Dec. 31, 2018	$ 22	$ 266,469	$ (274,601)	$ (8,110)
Balances (in shares) at Dec. 31, 2018	21,979,505
Issuance of common stock in exchange for services		68		68
Issuance of common stock in exchange for services, shares	16,486
Issuance of stock options for payment of compensation		195		195
Issuance of common stock for payment of compensation		90		90
Issuance of common stock for payment of compensation, shares	18,672
Issuance of common stock upon option exercise		325		325
Issuance of common stock upon option exercise, shares	97,725
Issuance of common stock upon note conversions		981		981
Issuance of common stock upon note conversions, shares	435,924
Convertible note beneficial conversion feature		143		143
Stock-based compensation expense		1,426		1,426
Net loss			(5,879)	(5,879)
Balances at Jun. 30, 2019	$ 22	269,697	(280,480)	(10,761)
Balances (in shares) at Jun. 30, 2019	22,548,312
Balances at Dec. 31, 2018	$ 22	266,469	(274,601)	(8,110)
Balances (in shares) at Dec. 31, 2018	21,979,505
Issuance of warrant for services
Issuance of common stock upon note conversions				981
Net loss				(8,268)
Balances at Sep. 30, 2019	$ 22	270,181	(282,869)	(12,666)
Balances (in shares) at Sep. 30, 2019	22,556,077
Balances at Jun. 30, 2019	$ 22	269,697	(280,480)	(10,761)
Balances (in shares) at Jun. 30, 2019	22,548,312
Issuance of common stock in exchange for services		3		3
Issuance of common stock in exchange for services, shares	706
Issuance of common stock for payment of compensation		30		30
Issuance of common stock for payment of compensation, shares	7,059
Stock-based compensation expense		451		451
Net loss			(2,389)	(2,389)
Balances at Sep. 30, 2019	$ 22	270,181	(282,869)	(12,666)
Balances (in shares) at Sep. 30, 2019	22,556,077
Balances at Dec. 31, 2019	$ 22	270,555	(284,895)	(14,318)
Balances (in shares) at Dec. 31, 2019	22,806,890
Issuance of common stock, net of expenses	$ 17	67,052		67,069
Issuance of common stock, net of expenses, shares	16,545,744
Issuance of common stock for conversion of debt	$ 3	4,313		4,316
Issuance of common stock for conversion of debt, shares	2,397,916
Issuance of common stock in exchange for services		70		70
Issuance of common stock in exchange for services, shares	21,331
Issuance of stock options for payment of compensation		165		165
Issuance of common stock for payment of compensation		48		48
Issuance of common stock for payment of compensation, shares	14,514
Issuance of warrant for services		118		118
Issuance of common stock upon option exercise
Issuance of common stock upon option exercise, shares	188,521
Stock-based compensation expense		622		622
Net loss			(26,489)	(26,489)
Balances at Jun. 30, 2020	$ 42	342,943	(311,384)	31,601
Balances (in shares) at Jun. 30, 2020	41,974,916
Balances at Dec. 31, 2019	$ 22	270,555	(284,895)	(14,318)
Balances (in shares) at Dec. 31, 2019	22,806,890
Issuance of warrant for services				2,066
Issuance of common stock upon note conversions				$ 4,316
Exercise of stock options, shares				429,330
Net loss				$ (57,240)
Balances at Sep. 30, 2020	$ 52	419,353	(342,135)	77,270
Balances (in shares) at Sep. 30, 2020	51,616,508
Balances at Jun. 30, 2020	$ 42	342,943	(311,384)	31,601
Balances (in shares) at Jun. 30, 2020	41,974,916
Issuance of common stock, net of expenses	$ 10	72,681		72,691
Issuance of common stock, net of expenses, shares	9,200,000
Issuance of common stock in exchange for services		142		142
Issuance of common stock in exchange for services, shares	13,733
Issuance of stock options for payment of compensation		15		15
Issuance of stock options for payment of compensation, shares
Issuance of common stock for payment of compensation		30		30
Issuance of common stock for payment of compensation, shares	2,803
Issuance of warrant for services		1,948		1,948
Issuance of common stock upon option exercise		572		572
Issuance of common stock upon option exercise, shares	202,147
Issance of common stock upon warrant exercise		10		10
Issance of common stock upon warrant exercise, shares	222,909
Stock-based compensation expense		1,012		1,012
Net loss			(30,751)	(30,751)
Balances at Sep. 30, 2020	$ 52	$ 419,353	$ (342,135)	$ 77,270
Balances (in shares) at Sep. 30, 2020	51,616,508

Nature of Operations

Nature of Operations	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Description of the Business The Company was incorporated on March 15, 2000 in California and reincorporated as a Delaware corporation in September 2001 under the name KaloBios Pharmaceuticals, Inc. Effective August 7, 2017, the Company changed its legal name to Humanigen, Inc. During February 2018, the Company completed the restructuring transactions announced in December 2017 and continued its transformation into a clinical-stage biopharmaceutical company by further The Company is focusing its efforts on the development of its lead product candidate, lenzilumab ™ in-vivo Lenzilumab is currently in a phase 3, multicenter, double-blind, placebo-controlled registrational trial for hospitalized, hypoxic patients with COVID-19 pneumonia. Based on discussions with the U.S. Food and Drug Administration (“FDA”), including a recent Type B meeting, the Company believes that the phase 3 trial could lead to a potential filing of an Emergency Use Authorization (“EUA”) application if data warrant such a filing. If the EUA were filed and granted, the Company could begin commercialization. The Company also intends to file a Biologics License Application (“BLA”) in 2021. Based on the discussion with FDA, the Company understands that a BLA will require the Company to generate and present more clinical data than would be required to support an EUA. The Company recently announced that lenzilumab will be included in the ACTIV-5 “Big Effect Trial” (ACTIV-5/BET). This study is sponsored by the National Institutes of Health (“NIH”). ACTIV-5/BET is designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and, therefore, merit advancement into larger clinical trials. ACTIV-5/BET, which is expected to enroll at as many as 40 US sites, will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients, with approximately 100 patients expected to be assigned to each study arm. The Company is providing lenzilumab for the study, which is fully funded by NIH. Lenzilumab is also being studied in a multicenter phase 1b/2 potential registrational trial as a sequenced therapy with Yescarta® (axicabtagene ciloleucel) to reduce CRS and neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”). This trial is being conducted in partnership with Kite Pharmaceuticals, Inc., a Gilead company (“Kite”), which markets Yescarta. The Company is also in the final planning stages for a Phase 2/3 trial for lenzilumab to treat patients who have undergone allogeneic hematopoietic stem cell therapy (“HSCT”) who are at high risk for acute GvHD. The trial is expected to be conducted by the IMPACT Partnership, a collection of 23 stem cell transplant centers located in the United Kingdom. The Company’s proprietary, patented Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to produce them. Lenzilumab and the Company’s other two product candidates, ifabotuzumab and HGEN005, are Humaneered monoclonal antibodies. The Company’s Humaneered antibodies are closer to human antibodies than chimeric or conventionally humanized antibodies and have a high affinity for their target but low immunogenicity. The Company believes its Humaneered antibodies offer additional advantages, such as lower likelihood to induce an inappropriate immune response or infusion related reaction, high potency, and a slow off-rate. See Management’s Discussion and Analysis of Financial Condition and Results of Operations in Item 2 of this Quarterly Report on Form 10-Q for additional information regarding the business. Liquidity and Going Concern The Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2020 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These conditions raised substantial doubt about the Company’s ability to continue as a going concern as described in the Company’s historical Condensed Consolidated Financial Statements included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020. Following completion of its underwritten public offering in September 2020, as of September 30, 2020, the Company had cash and cash equivalents of $91.5 million (see Note 6). Accordingly, the Company re-evaluated its potential going concern disclosure requirements in accordance with ASC 205-40-50 as of September 30, 2020. Upon completion of this evaluation, the Company has concluded that its existing cash and cash equivalents have alleviated that prior substantial doubt about the Company’s ability to continue as a going concern. The Company believes that its cash and cash equivalents will be sufficient to fund its planned operations and capital expenditure requirements for at least 12 months. This evaluation is based on relevant conditions and events that are currently known or reasonably knowable. As a result, the Company could deplete its available capital resources sooner than it currently expects, and a delay in obtaining or failure to obtain an EUA could further constrain its cash resources. The Company has based these estimates on assumptions that may prove to be wrong, and its operating projections, including its projected net revenue following the potential receipt of an EUA for lenzilumab in COVID-19 patients, may change as a result of many factors currently unknown to it. If the Company is unable to raise additional capital when needed or on acceptable terms, it would be forced to delay, reduce or eliminate its research and development programs and commercialization efforts. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements included herein do not include any adjustments that might result from the outcome of these uncertainties. Basis of Presentation The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements and include all adjustments necessary for the presentation of the Company’s condensed consolidated financial position, results of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. These financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The December 31, 2019 Condensed Consolidated Balance Sheet was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2020, or for any other future annual or interim period. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company’s 2019 Form 10-K. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in determining the valuation of the fair value-based measurement of stock-based compensation and warrant valuations. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Condensed Consolidated Financial Statements. Certain prior year amounts have been reclassified to conform to the current year presentation. Such reclassifications had no effect on prior years’ Net loss or Stockholders’ equity (deficit). Effective 4:30 p.m. Eastern Time on September 11, 2020 (the “Effective Time”), the Company amended its charter to effect a reverse stock split at a ratio of 1-for-5 (the “Split Ratio”). No fractional shares were issued in connection with the reverse stock split. Stockholders of record otherwise entitled to receive fractional shares of common stock received cash (without interest or deduction) in lieu of such fractional share interests. The reverse stock split reduced the total number of shares of the Company’s common stock outstanding as of the Effective Time from approximately 210.9 million shares to approximately 42.2 million shares. The par value per share and other terms of the Company’s common stock were not affected by the reverse stock split, and the number of authorized shares of the Company’s common stock remains at 225,000,000. The reverse stock split resulted in a proportionate adjustment in the number of shares reserved for issuance under the Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan (the “2020 Equity Plan”), such that a total of 7,000,000 shares of the Company’s common stock were reserved for issuance under the 2020 Equity Plan following the Effective Time. In addition, proportionate adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award under the Humanigen, Inc. 2012 Equity Incentive Plan (the “2012 Equity Plan”) and outstanding warrants issued by the Company, in each case to give effect to the Split Ratio and the reverse stock split. The reverse stock split was accounted for retroactively and is reflected in our common stock, stock option and warrant activity as of and during the year ended December 31, 2019 and the periods ended September 30, 2020 and 2019. Unless stated otherwise, all share data in this Quarterly Report on Form 10-Q have been adjusted, as appropriate, to reflect the reverse stock split.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies since those previously disclosed in the 2019 Form 10-K.

Potentially Dilutive Securities

Potentially Dilutive Securities	9 Months Ended
	Sep. 30, 2020
Potentially Dilutive Securities
Potentially Dilutive Securities	3. Potentially Dilutive Securities The Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per common share as the effect of including those securities would be to reduce the net loss per common share and be antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in each period presented. The following outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share: As of September 30, 2020 2019 Options to purchase common stock 3,528,642 3,027,875 Warrants to purchase common stock 76,238 66,239 3,604,880 3,094,114

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	4. Debt Notes Payable to Vendors On June 30, 2016, the Company issued promissory notes in an aggregate principal amount of approximately $1.2 million to certain claimants in accordance with the Company’s Plan of Reorganization (the “Plan”) filed with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) (Case No. 15-12628 (LSS) (the “Bankruptcy Case”) which became effective June 30, 2016, at which time the Company emerged from its Chapter 11 bankruptcy proceedings. The notes were unsecured, accrued interest at 10% per annum and became due and payable in full, including principal and accrued interest on June 30, 2019. In July and August, 2019, following the receipt of proceeds from the 2019 Bridge Notes, the Company used approximately $0.5 million of the proceeds to retire a portion of these notes, including accrued interest. After giving effect to these payments, the aggregate principal amount and accrued but unpaid interest on these notes approximated $1.1 million as of December 31, 2019 and the Company had accrued $0.3 million in interest expense. In June and July 2020, the Company used the proceeds from the Private Placement (as defined below) to repay the remaining outstanding principal including accrued and unpaid interest on these notes and the notes were extinguished. As of September 30, 2020, all the notes have been repaid. Advance Notes In June, July and August, 2018 the Company received an aggregate of $0.9 million of proceeds from advances made to the Company (the “Advance Notes”) by four different lenders including Dr. Cameron Durrant, the Company’s Chairman and Chief Executive Officer; Cheval Holdings, Ltd. (“Cheval”), an affiliate of Black Horse Capital, L.P. (“BHC”), the Company’s controlling stockholder at the time; and Ronald Barliant, a director of the Company. The Advance Notes accrued interest at a rate of 7% per year, compounded annually. In accordance with their terms, on May 30, 2019, in connection with the Company’s announcement of the Collaboration Agreement with Kite, the lenders converted the amounts due under the Advance Notes into the Company’s common stock at the conversion price of $2.25 per share. The Company issued a total of 435,924 shares of common stock in connection with the conversion. 2018 Convertible Notes Commencing September 19, 2018, the Company delivered a series of convertible promissory notes (the “2018 Notes”) evidencing an aggregate of $2.5 million of loans made to the Company by six different lenders, including an affiliate of BHC, the Company’s controlling stockholder at the time. The 2018 Notes accrued interest at a rate of 7% per annum and, in general, were set to mature twenty-four months from the date the 2018 Notes were signed. The Company used the proceeds from the 2018 Notes for working capital. The 2018 Notes were convertible into equity securities of the Company in three different scenarios, including if the Company sold its equity securities on or before the date of repayment of the 2018 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $10 million (a “Non-Qualified Financing”). In connection with a Non-Qualified Financing, the noteholders were able to convert their remaining 2018 Notes into either (i) such equity securities as the noteholder would acquire if the principal and accrued but unpaid interest thereon (the “Conversion Amount”) were invested directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $2.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Notes). The Company’s sales of shares pursuant to the ELOC Purchase Agreement with Lincoln Park Capital Fund, LLC (“LPC”) constituted a Non-Qualified Financing. Commencing on April 2, 2020, the holders of the 2018 Notes notified the Company of their exercise of their conversion rights under the 2018 Notes. See “2019 Convertible Notes” for additional information regarding the conversion of 2018 Notes by the holders. As of December 31, 2019, the Company had accrued $0.2 million in interest related to these promissory notes. Interest expense recorded during the three and nine months ended September 30, 2020 was approximately $0 and $817 thousand, respectively. 2019 Convertible Notes Commencing on April 23, 2019, the Company delivered a series of convertible promissory notes (the “2019 Notes” and together with the 2018 Notes, the “Convertible Notes”) evidencing an aggregate of $1.3 million of loans made to the Company. The 2019 Notes accrued interest at a rate of 7.5% per annum and, in general, were set to mature twenty-four months from the date the 2019 Notes were signed. The Company used the proceeds from the 2019 Notes for working capital. The 2019 Notes were convertible into equity securities of the Company in four different scenarios, including if the Company sold its equity securities on or before the date of repayment of the 2019 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $10 million (a “Non-Qualified Financing”). In connection with a Non-Qualified Financing, the noteholders were able to convert their remaining 2019 Notes into either (i) such equity securities as the noteholder would acquire if the Conversion Amount were invested directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $6.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the 2019 Notes). The Company’s sales of shares pursuant to the ELOC Purchase Agreement with LPC constituted a Non-Qualified Financing. Commencing on April 2, 2020, holders of the Convertible Notes, including Cheval, an affiliate of BHC, the Company’s controlling stockholder at the time, notified the Company of their exercise of their conversion rights under the Convertible Notes. Pursuant to the exemption from registration afforded by Section 3(a)(9) under the Securities Act, the Company issued an aggregate of 2,397,915 shares of its common stock upon the conversion of $4.3 million in aggregate principal and interest on the Convertible Notes that were converted, which obligations were retired. Of these, the Company issued 316,666 shares to Cheval. Dr. Dale Chappell, who was serving as the Company’s ex-officio chief scientific officer at the time and currently serves as its Chief Scientific Officer, controls BHC and reports beneficial ownership of all shares held by it and its affiliates, including Cheval. After giving effect to the shares issued upon such conversions, no convertible notes issued in 2018 or 2019 were outstanding as of September 30, 2020. As of December 31, 2019, the Company had accrued $0.1 million in interest related to the 2019 Notes. Interest expense related to the 2019 Notes, recorded during the three and nine months ended September 30, 2020, was approximately $0 and $219 thousand, respectively. The Advance Notes, the 2018 Notes and the 2019 Notes had an optional voluntary conversion feature in which the holder could convert the notes in the Company’s common stock at maturity at a conversion rate of $2.25 per share for the Advance Notes and the 2018 Notes and at a conversion rate of $6.25 for the 2019 Notes. The intrinsic value of this beneficial conversion feature was $1.8 million upon the issuance of the Advance Notes, the 2018 Notes and the 2019 Notes and was recorded as additional paid-in capital and as a debt discount which is accreted to interest expense over the term of the Advance Notes and Notes. Interest expense includes debt discount amortization of $0 and $785 thousand for the three and nine months ended September 30, 2020, respectively. The Company evaluated the embedded features within the Advance Notes, the 2018 Notes and the 2019 Notes to determine if the embedded features are required to be bifurcated and recognized as derivative instruments. The Company determined that the Advance Notes, the 2018 Notes and the 2019 Notes contain contingent beneficial conversion features (“CBCF”) that allow or require the holder to convert the Advance Notes, the 2018 Notes and the 2019 Notes, as applicable, to Company common stock at a conversion rate of $2.25 per share for the Advance Notes and the 2018 Notes and $6.25 for the 2019 Notes, but did not contain embedded features requiring bifurcation and recognition as derivative instruments. Upon the occurrence of a CBCF that results in conversion of the Advance Notes, the 2018 Notes or the 2019 Notes to Company common stock, the remaining unamortized discount will be charged to interest expense. Upon conversion of the Advance Notes on May 30, 2019, the remaining unamortized discount was charged to interest expense. Upon the conversion of the Convertible Notes in April 2020, the remaining related unamortized discount was charged to interest expense. 2020 Convertible Redeemable Notes On March 13, 2020 and March 19, 2020 (the “Issuance Dates”), the Company delivered two convertible redeemable promissory notes (the “2020 Notes”) evidencing loans with an aggregate principal amount of $518,333 made to the Company. The 2020 Notes accrued interest at a rate of 7.0% per annum and were set to mature on March 13, 2021 and March 19, 2021, respectively. The 2020 Notes contained an original issue discount of $33,000 and $18,833, respectively. The Company used the proceeds from the 2020 Notes for working capital. The notes could be redeemed by the Company at any time before the 270 th The Company evaluated the embedded features within the 2020 Notes and determined that the embedded features are required to be bifurcated and recognized as stand-alone derivative instruments. The variable-share settlement features within the 2020 Notes qualify as redemption features and meet the net settlement criterion for qualification as a stand-alone derivative. In determining the fair value of the bifurcated derivative, the Company evaluated the likelihood of conversion of the 2020 Notes to Company stock. As the Company believed it would have adequate funding prior to the six month anniversary of the 2020 Notes, the first conversion option for the holders of the 2020 Notes, and it had the intent to either begin making amortizing payments or to pay off the 2020 Notes in their entirety prior to that date, the fair value was determined to be $0. The original issue discount was accreted to Interest expense and the remaining balance was charged to Interest expense upon payoff. Interest expense related to the 2020 Notes, recorded during the three and nine months ended September 30, 2020, was approximately $0 and $165 thousand, respectively. Interest expense includes the original issue discount amortization of approximately $0 and $52 thousand for the three and nine months ended September 30, 2020, respectively. Bridge Notes On June 28, 2019, the Company issued three short-term, secured bridge notes (the “June Bridge Notes”) evidencing an aggregate of $1.7 million of loans made to the Company by three parties: Cheval , an affiliate of BHC, the Company’s controlling stockholder at the time, lent $750,000; Nomis Bay LTD, the Company’s second largest stockholder, lent $750,000; and Dr. Cameron Durrant, the Company’s Chief Executive Officer and Chairman of the Board of Directors (the “Board”), lent $200,000. The proceeds from the June Bridge Notes were used to satisfy a portion of the unsecured obligations incurred in connection with the Company’s emergence from bankruptcy in 2016 and for working capital and general corporate purposes. Of the $1.7 million in proceeds received, $950,000 was received on June 28, 2019 and was recorded as Advance notes in the Condensed Consolidated Balance Sheet as of June 30, 2019. The remaining proceeds of $750,000 were received July 1, 2019 and recorded accordingly. The June Bridge Notes accrued interest at a rate of 7.0% per annum and after giving effect to multiple extensions, were set to mature on December 31, 2020. The June Bridge Notes could become due and payable at such earlier time as the Company raised more than $3,000,000 in a bona fide financing transaction or upon a change in control. Accordingly, the June Bridge Notes were repaid in June 2020 with proceeds from the Private Placement, and the June Bridge Notes were extinguished. On November 12, 2019, the Company issued two short-term, secured bridge notes (the “November Bridge Notes” and together with the June Bridge Notes, the “2019 Bridge Notes”) evidencing an aggregate of $350,000 of loans made to the Company by two parties: Cheval, an affiliate of BHC, our controlling stockholder at the time, lent $250,000; and Dr. Cameron Durrant, our Chief Executive Officer and Chairman of our Board, lent $100,000 The November Bridge Notes ranked on par with the June Bridge Notes and possessed other terms and conditions substantially consistent with those notes. The November Bridge Notes accrued interest at a rate of 7.0% per annum and after giving effect to multiple extensions, were set to mature on December 31, 2020. The November Bridge Notes could become due and payable at such earlier time as the Company raised more than $3,000,000 in a bona fide financing transaction or upon a change in control. Accordingly, the November Bridge Notes were repaid in June 2020 with proceeds from the Private Placement. In April 2020, the Company issued two short-term, secured bridge notes (the “April Bridge Notes” and together with the June Bridge Notes and the November Bridge Notes, the “Bridge Notes”) evidencing an aggregate of $350,000 of loans made to the Company: Cheval, an affiliate of BHC, the Company’s controlling stockholder at the time, loaned $100,000, and Nomis Bay, the Company’s second largest stockholder, loaned $250,000. The proceeds from the April Bridge Notes were used for working capital and general corporate purposes. The April Bridge Notes ranked on par with the June Bridge Notes and the November Bridge Notes and possessed other terms and conditions substantially consistent with them. The notes accrued interest at a rate of 7.0% per annum and were set to mature on December 31, 2020. The April Bridge Notes could become due and payable at such earlier time as the Company raised more than $10,000,000 in a bona fide financing transaction or upon a change in control. Accordingly, these April Bridge Notes were repaid in June 2020 with proceeds from the Private Placement, and these bridge notes were extinguished. The Bridge Notes were secured by a lien on substantially all the Company’s assets, which liens have been released. Interest expense related to the Bridge Notes, recorded during the three and nine months ended September 30, 2020, was approximately $0 and $66 thousand, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Contractual Obligations and Commitments As of September 30, 2020, other than the retirement and conversion of certain debt described in Note 4 and the license agreements described in Note 7, there were no material changes to the Company’s contractual obligations from those set forth in the 2019 Form 10-K. Guarantees and Indemnifications The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for, or expenses related to, indemnification issues for any period presented.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	6. Stockholders’ Equity Reverse Stock Split Effective as of 4:30 p.m. Eastern Time on September 11, 2020 (the “Effective Time”), the Company amended its charter to effect a reverse stock split at a ratio of 1-for-5 (the “Split Ratio”). No fractional shares were issued in connection with the reverse stock split. Stockholders of record otherwise entitled to receive fractional shares of common stock received cash (without interest or deduction) in lieu of such fractional share interests. The reverse stock split reduced the total number of shares of the Company’s common stock outstanding as of the Effective Time from approximately 210.9 million shares to approximately 42.2 million shares. The par value per share and other terms of the Company’s common stock were not affected by the reverse stock split, and the number of authorized shares of the Company’s common stock remains at 225,000,000. The reverse stock split resulted in a proportionate adjustment in the number of shares reserved for issuance under the 2020 Equity Plan, such that a total of 7,000,000 shares of the Company’s common stock were reserved for issuance under the 2020 Equity Plan following the Effective Time. In addition, proportionate adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award under the 2012 Equity Plan and outstanding warrants issued by the Company, in each case to give effect to the Split Ratio and the reverse stock split. The reverse stock split was accounted for retroactively and is reflected in our common stock, stock option and warrant activity as of and during the period ended December 31, 2019 and the periods ended September 30, 2020 and 2019. Unless stated otherwise, all share data in this Quarterly Report on Form 10-Q have been adjusted, as appropriate, to reflect the reverse stock split. Lincoln Park Capital Purchase Agreement On November 8, 2019, the Company entered into a purchase agreement (the “ELOC Purchase Agreement”) and a registration rights agreement with LPC, pursuant to which the Company had the right to sell to LPC up to $20,000,000 in shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), subject to certain limitations and conditions set forth in the ELOC Purchase Agreement. In connection with the signing of the ELOC Purchase Agreement on November 8, 2019, the Company issued 141,318 shares of its common stock to LPC. The issuance of the shares was recorded as debt issuance costs in Common stock and Additional paid-in capital with no net effect on Stockholders’ equity (deficit). During the months of December 2019 and January 2020, the Company issued a total of 140,000 shares for aggregate proceeds of $0.3 million under the ELOC Purchase Agreement. On June 2, 2020, following completion of the Private Placement described below, the Company notified LPC of its decision to terminate the ELOC Purchase Agreement. The termination of the ELOC Purchase Agreement became effective on June 3, 2020. 2020 Private Placement On June 1, 2020, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”) to complete a private placement of our common stock (the “Private Placement”). The closing of the Private Placement occurred on June 2, 2020 (the “Closing Date”). At the closing, the Company issued and sold 16,505,743 shares of its common stock (the “Shares”) at a purchase price of $4.35 per share, for aggregate gross proceeds of approximately $71.8 million. The Company used a portion of the proceeds to retire certain indebtedness, as further described in Note 4 - Debt. See Note 9 for information regarding two complaints filed against us in connection with the Private Placement. On the Closing Date, the Company and the Investors also entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company agreed to prepare and file a registration statement (the “Resale Registration Statement”) for the resale of the Shares with the Securities and Exchange Commission (the “SEC”). Subject to certain limitations and an overall cap, the Company may be required to pay liquidated damages to the investors at a rate of 2% of the invested capital for each occurrence (and continuation for 30 consecutive days thereafter) of a breach by the Company of certain of its obligations under the Registration Rights Agreement. The Purchase Agreement also required that the Company use its commercially reasonable efforts to achieve a listing of the Common Stock on a national securities exchange, subject to certain limitations set forth in the Purchase Agreement. On July 6, 2020, the Company applied to have its common stock approved for listing on the Nasdaq Capital Market. On September 18, 2020, the Company’s common stock commenced trading on the Nasdaq Capital Market under the symbol “HGEN.” 2020 Underwritten Public Offering On September 17, 2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters, in connection with the public offering of 8,000,000 of the Company’s shares of common stock. Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of common stock, which option was exercised in full by the underwriters on September 18, 2020 As a result of the pricing of the public offering, the Company’s common stock commenced trading on the Nasdaq Capital Market under the symbol “HGEN.” The aggregate gross proceeds from the sale of the full 9,200,000 shares in the offering were approximately $78.2 million. The Company expects to use the proceeds from the offering to support its manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy for COVID-19 patients and for working capital and other general corporate purposes. 2020 Equity Plan On July 27, 2020, the Board unanimously approved, and recommended that the Company’s stockholders approve, the 2020 Equity Plan, to ensure that the Board and its compensation committee (the “Compensation Committee”) will be able to make the types of awards, and covering the number of shares, as necessary to meet the Company’s compensatory needs. On July 29, 2020, the 2020 Equity Plan was approved by the holders of approximately 63% of the Company’s outstanding shares of common stock on that date. The 2020 Equity Plan became effective on September 11, 2020 following the Effective Time of the reverse stock split. Immediately following the Effective Time, a total of 7,000,000 shares of the Company’s common stock were reserved for issuance under the 2020 Equity Plan. The Board or Compensation Committee may grant the following types of awards under the 2020 Equity Plan: stock options, stock appreciation rights, restricted stock, stock awards, restricted stock units, performance shares, performance units, cash-based awards and substitute awards. The 2020 Equity Plan will remain in effect until the tenth anniversary of its effective date, unless terminated earlier by the Board. 2012 Equity Plan The 2020 Equity Plan replaced the 2012 Equity Plan, under which no further grants will be made. However, any outstanding awards under the 2012 Equity Plan will continue in accordance with the terms of the 2012 Equity Plan and any award agreement executed in connection with such outstanding awards. At the Effective Time of the reverse stock split, proportionate adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award under the 2012 Equity Plan to give effect to the Split Ratio and the reverse stock split. Under the 2012 Equity Plan, the Company could grant shares, stock units, stock appreciation rights, performance cash awards and/or options to employees, directors, consultants, and other service providers. For options, the per share exercise price could not be less than the fair market value of a Company common share on the date of grant. Awards generally vest and become exercisable over three to four years and expire 10 years from the date of grant. Options generally become exercisable as they vest following the date of grant. A summary of stock option activity for the nine months ended September 30, 2020 under all the Company’s options plans is as follows: Options Weighted Average Outstanding at January 1, 2020 3,176,336 $ 4.73 Granted 781,657 6.59 Exercised (429,330 ) (3.55 ) Cancelled (expired) (21 ) (58.40 ) Outstanding at September 30, 2020 3,528,642 $ 5.30 The weighted average fair value of options granted during the nine months ended September 30, 2020 was $5.13 per share. The Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption terms for the nine months ended : Nine Months Ended September 30, 2020 Exercise price $1.90 - $10.64 Market value $1.90 - $10.64 Expected term 5 - 6 years Expected volatility 94.6% - 103.7% Risk-free interest rate 0.28% - 1.57% Expected dividend yield - % Stock-Based Compensation The Company recorded stock-based compensation expense in the Condensed Consolidated Statements of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 General and administrative $ 909 $ 419 $ 1,415 $ 1,813 Research and development 103 $ 32 219 64 Total stock-based compensation $ 1,012 $ 451 $ 1,634 $ 1,877 At September 30, 2020, the Company had $3.8 million of total unrecognized stock-based compensation expense, net of estimated forfeitures, related to outstanding stock options that will be recognized over a weighted-average period of 2.4 years.

License and Collaboration Agree

License and Collaboration Agreements	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
License and Collaboration Agreements	7. License and Collaboration Agreements Kite Agreement On May 30, 2019, the Company entered into a collaboration agreement (the “Kite Agreement”) with Kite Pharmaceuticals, Inc., pursuant to which the Company and Kite are conducting a multi-center Phase 1b/2 study of lenzilumab with Kite’s Yescarta in patients with relapsed or refractory B-cell lymphoma, including diffuse large B-cell lymphoma (“DLBCL”). The primary objective of the study is to determine the effect of lenzilumab on the safety of Yescarta. Pursuant to the Kite Agreement, the Company shall supply lenzilumab to the collaboration for use in the study and will contribute up to approximately $8.0 million towards the out-of-pocket costs of the study, depending on the number of patients enrolled into the study. During the month of September 2020, the Company paid $2.0 million to Kite towards its contribution for the study, which payment was recorded as Research and development expense in the three months ended September 30, 2020. Mayo Agreement On June 19, 2019 the Company entered into an exclusive worldwide license agreement (the “Mayo Agreement”) with the Mayo Foundation for Medical Education and Research (“Mayo”) for certain technologies used to create CAR-T cells lacking GM-CSF expression through various gene-editing tools including CRISPR-Cas9 (GM-CSF knock-out). The license covers various patent applications and know-how developed by Mayo in collaboration with the Company. These licensed technologies complement and broaden the Company’s position in the GM-CSF neutralization space and expand the Company’s discovery platform aimed at improving CAR-T to include gene-edited CAR-T cells. Pursuant to the Mayo Agreement, the Company agreed to pay $200,000 to Mayo within six months of the effective date, or upon completion of a qualified financing, whichever is earlier. The Mayo Agreement also requires the payment of milestones and royalties upon the achievement of certain regulatory and commercialization milestones. The initial payment was recorded as Research and development expense in June 2019. The Company paid the initial payment in June 2020 subsequent to the closing of the Private Placement. Zurich Agreement On July 19, 2019 the Company entered into an exclusive worldwide license agreement (the “Zurich Agreement”) with the University of Zurich (“UZH”) for technology used to prevent or treat Graft versus Host Disease (“GvHD”) through GM-CSF neutralization. The Zurich Agreement covers various patent applications filed by UZH which complement and broaden the Company’s position in the application of GM-CSF and expands the Company’s development platform to include improving allogeneic Hematopoietic Stem Cell Transplantation (“HSCT”). Pursuant to the Zurich Agreement, the Company paid $100,000 to UZH in July 2019. The Zurich Agreement also requires the payment of annual maintenance fees and milestones and royalties upon the achievement of certain regulatory and commercialization milestones. The license payment of $100,000 was recorded as Research and development expense in July 2019. Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases On July 24, 2020, the Company entered into a clinical trial agreement (the “Clinical Trial Agreement”) with the National Institute of Allergy and Infectious Diseases (“NIAID”), part of NIH, which is part of the United States Government Department of Health and Human Services, as represented by the Division of Microbiology and Infectious Diseases. Pursuant to the Clinical Trial Agreement, lenzilumab will be an agent to be evaluated in NIAID-sponsored Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-5 and Big Effect Trial (“BET”), referred to as ACTIV-5/BET, in hospitalized patients with COVID-19. The NIH created the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and selected lenzilumab to be evaluated in its ACTIV-5/BET, which will compare lenzilumab with Gilead’s investigational antiviral, remdesivir, versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial is expected to enroll 100 patients in each arm of the study with an interim analysis for efficacy after 50 patients have been enrolled in each arm. Pursuant to the Clinical Trial Agreement, NIAID will serve as sponsor and will be responsible for funding, supervising and overseeing ACTIV-5/BET. The Company will be responsible for providing lenzilumab to NIAID without charge and in quantities to ensure a sufficient supply of lenzilumab. The Clinical Trial Agreement imposes additional obligations on the Company that are reasonable and customary for clinical trial agreements of this nature, including in respect of compliance with data privacy laws and potential indemnification obligations.

Savant Arrangements

Savant Arrangements	9 Months Ended
	Sep. 30, 2020
Savant Arrangements
Savant Arrangements	8. Savant Arrangements On June 30, 2016 the Company and Savant Neglected Diseases, LLC (“Savant”) entered into an Agreement for the Manufacture, Development and Commercialization of Benznidazole for Human Use (the “MDC Agreement”), pursuant to which the Company acquired certain worldwide rights relating to benznidazole (the “Compound”). In addition, on the Effective Date the Company and Savant also entered into a Security Agreement (the “Security Agreement”), pursuant to which the Company granted Savant a continuing senior security interest in the assets and rights acquired by the Company pursuant to the MDC Agreement and certain future assets developed from those acquired assets. On the effective date, the Company issued to Savant a five-year warrant (the “Warrant”) to purchase 40,000 shares of the Company’s Common Stock, at an exercise price of $11.25 per share, subject to adjustment. As of June 30, 2020, the Warrant was exercisable for 20,000 shares at an exercise price of $11.25 per share. On July 20, 2020, the Company issued to Savant a total of 10,909 shares of its common stock pursuant to a “net exercise” of the Warrant by Savant. The Warrant is not expected to vest or become exercisable for any additional shares of the Company’s common stock. As a result of the FDA granting accelerated and conditional approval of a benznidazole therapy manufactured by a competitor for the treatment of Chagas disease and awarding such competitor a neglected tropical disease PRV in August 2017, the Company ceased development of benznidazole and re-evaluated the final two vesting milestones and concluded that the probability of achievement of these milestones had decreased to 0%. In July 2017, the Company commenced litigation against Savant alleging that Savant breached the MDC Agreement and seeking a declaratory judgement. Savant has asserted counterclaims for breaches of contract under the MDC Agreement and the Security Agreement. The dispute primarily concerns the Company’s right under the MDC Agreement to offset certain costs incurred by the Company in excess of the agreed upon budget against payments due Savant. See Note 9, below, for more information regarding the Savant litigation. The aggregate cost overages as of June 30, 2017 that the Company asserts are Savant’s responsibility total approximately $3.4 million, net of a $0.5 million deductible. The Company asserts that it is entitled to offset $2.0 million in milestone payments due Savant against the cost overages, such that as of June 30, 2017, Savant owed the Company approximately $1.4 million. As of June 30, 2019, the cost overages totaled $4.1 million such that Savant owed the Company approximately $2.1 million in cost overages. Such cost overages have been charged to Research and development expense as incurred. Recovery of such cost overages, if any, will be recorded as a reduction of Research and development expense in the period received. The $2.0 million in milestone payments due Savant are included in Accrued expenses in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2020
Litigation Settlement [Abstract]
Litigation	9. Litigation Savant Litigation On July 10, 2017, the Company filed a complaint against Savant in the Superior Court for the State of Delaware, New Castle County (the “Delaware Court”). KaloBios Pharmaceuticals, Inc. v. Savant Neglected Diseases, LLC On July 12, 2017, Savant removed the case to the Bankruptcy Court, claiming that the action is related to or arises under the Bankruptcy Case from which we emerged in July 2016. In re KaloBios Pharmaceuticals, Inc. On August 2, 2017, Savant sent a foreclosure notice to the Company, demanding that it provide the Collateral as defined in the Security Agreement for inspection and possession on August 9, 2017, with a public sale to be held on September 1, 2017. The Company moved for a Temporary Restraining Order (the “TRO”) and Preliminary Injunction in the Bankruptcy Court on August 4, 2017. Savant responded on August 7, 2017. On August 7, 2017, the Bankruptcy Court granted the Company’s motion for a TRO, entering an order prohibiting Savant from collecting on or selling the Collateral, entering our premises, issuing any default notices to us, or attempting to exercise any other remedies under the MDC Agreement or the Security Agreement. On August 9, 2017, the parties have stipulated to continue the provisions of the TRO in full force and effect until further order of the appropriate court, which the Bankruptcy Court signed that same day (the “Stipulated Order”). On January 22, 2018, Savant wrote to the Bankruptcy Court requesting dissolution of the TRO and the Stipulated Order. On January 29, 2018, the Bankruptcy Court granted the Motion to Remand and denied Savant’s request to dissolve the TRO and Stipulated Order, ordering that any request to dissolve the TRO and Stipulated Order be made to the Delaware Court. On February 13, 2018 Savant made a letter request to the Delaware Court to dissolve the TRO and Stipulated Order. Also, on February 13, 2018, the Company filed its Answer and Affirmative defenses to Savant’s Counterclaims. On February 15, 2018 the Company filed a letter opposition to Savant’s request to dissolve the TRO and Stipulated Order and requesting a status conference. A hearing on Savant’s request to dissolve the TRO and Stipulated Order was held before the Delaware Court on March 19, 2018. The Delaware Court denied Savant’s request to dissolve the TRO and Stipulated order, which remain in effect. On April 11, 2018, the Company advised the Delaware Court that it would meet and confer with Savant regarding a proposed case management order and date for trial. On April 26, 2018 the Delaware Court so-ordered a proposed case management order submitted by the Company and Savant. The schedule in the case management order was modified by stipulation on August 24, 2018. On April 8, 2019, the Company moved to compel Savant to produce documents in response to the Company’s document requests. The parties thereafter agreed to a discovery schedule through June 30, 2019, which the Superior Court so-ordered, and the parties produced documents to each other. On June 4, 2019, Savant filed a complaint against the Company and Madison in the Delaware Court of Chancery (the “Chancery Action”) seeking to “recover as damages that amounts owed to it under the MDC Agreement, and to reclaim Savant’s intellectual property,” among other things. Savant also requested leave to move to dismiss the Company’s complaint on the grounds that the Company’s transfer of assets to Madison was champertous. On June 10, 2019, the Company requested by letter that the Superior Court hold a contempt hearing because the Chancery Action violated the TRO entered by the Bankruptcy Court, the terms of which have been extended by stipulation of the parties. On June 18, 2019, the Superior Court held a telephonic status conference. The parties agreed that the Chancery Action should be consolidated with the Superior Court action, after which the Superior Court would address the parties’ motions. On July 22, 2019, the Company moved for contempt against Savant. Savant filed its opposition on July 29, 2019. On August 12, 2019, the Superior Court denied the Company’s motion for contempt. On July 23, 2019, Savant moved for summary judgment on the issue of champerty. The Company filed its response and cross-motion for summary judgment on August 27, 2019. Savant filed its reply on September 10, 2019 and the Company filed its cross-reply on September 20, 2019. The motion is fully briefed and was argued at a hearing on February 3, 2020. The court has not yet ruled on the motion. On July 26, 2019, the Company moved to modify the previously agreed-upon discovery schedule to extend discovery through December 31, 2019, which the Superior Court granted. In subsequent orders, the discovery schedule was further extended until the end of June 2020. On July 30, 2019, the Company filed a motion to dismiss Savant’s Chancery Action. Savant filed an amended complaint on September 4, 2019, and the Company filed its opening brief in support of its motion to dismiss on October 11, 2019. That motion is fully briefed and was argued at a hearing on February 3, 2020. The court has not yet ruled on the motion. On August 19, 2019, Savant moved to dismiss the Company’s amended Superior Court complaint. On September 27, 2019, the Company filed an opposition to Savant’s motion and, in the alternative, requested leave to file a second amended complaint against Savant. Savant consented to the filing of the second amended complaint and withdrew their motion to dismiss. Savant filed a partial motion to dismiss against a co-defendant on October 30, 2019. That motion is fully briefed and was argued at a hearing on February 3, 2020. At the February 3, 2020 hearing, the Court reserved judgment on the parties’ reciprocal motions. On May 22, 2020, upon the request of the parties, the Superior Court stayed both Delaware actions until July 29, 2020. On June 30, 2020, Savant exercised 20,000 warrants in a cashless exercise resulting in 10,909 shares being issued to Savant. On July 24, 2020, the parties submitted a joint status report in the Delaware actions. The parties also requested a status conference with the Court to discuss moving the trial from October 2020 to some later time. On August 20, 2020, the Court held the requested status conference and ordered that a consolidated trial for the Superior Court Action and Chancery Action would be held in April 2021. The parties subsequently agreed to a five-day trial starting on April 12, 2021. On October 7, 2020, Savant moved for leave to amend its complaint in the Chancery Action to add a claim for breach of contract related to its exercise of 20,000 warrants. Savant claims that the Company’s issuance of 10,909 shares was insufficient under the warrant. Private Placement Litigation On June 15, 2020, a complaint was filed against Humanigen and Dr. Durrant in the Commercial Division of the Supreme Court of the State of New York. The case caption is Alliance Texas Holdings, LLC et al. v. Humanigen, Inc. et al. On June 19, 2020, Noble filed a separate complaint against Humanigen in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, also arising from the Private Placement. On July 13, 2020, the Defendants removed Noble’s complaint to United States District Court for the Southern District of Florida. The case caption is Noble Capital Markets, Inc. v. Humanigen, Inc. The Company believes that the claims made in each complaint are without merit, and it is prepared to defend itself vigorously.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On October 5, 2020, the Company’s Compensation Committee determined that the Company had achieved or exceeded the original fiscal year 2020 performance criteria and objectives, previously established in connection with the Company’s 2020 annual incentive plan. As a result, the Board (with Dr. Cameron Durrant, the Company’s Chairman and Chief Executive Officer, abstaining) unanimously approved the acceleration of the payout of a portion of Dr. Durrant’s fiscal year 2020 bonus. Dr. Durrant will remain eligible to receive additional payouts under the 2020 annual incentive plan to the extent the Board determines that the Company has achieved certain additional and stretch goals for 2020. Based on the Company’s achievement of certain pre-established fiscal year 2020 performance criteria and objectives, Dr. Durrant was awarded a fiscal year 2020 bonus of $1,512,000, with 50% of such bonus being paid in cash and 50% being awarded in stock options. The options were fully vested on the grant date. On October 13, 2020 the Company announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, launched its ACTIV-5 "Big Effect Trial" (ACTIV-5/BET), designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and, therefore, merit advancement into larger clinical trials. ACTIV-5/BET, which is expected to enroll at as many as 40 US sites, will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients with approximately 100 patients expected to be assigned to each study arm. Humanigen is providing lenzilumab for the study, which is fully funded by NIH. On October 29, 2020, the Company entered into an amended and restated employment agreement (the “New Agreement”) with Dr. Durrant. The New Agreement replaces Dr. Durrant’s previous employment agreement with the Company (the “Prior Agreement”). Consistent with the terms of the Prior Agreement, the New Agreement provides that Dr. Durrant’s annual base salary will remain at $600,000 and he will remain eligible for an annual bonus targeted at 60% of his base salary, with Dr. Durrant’s base salary and target bonus subject to review by the Board in connection with its regular review of the Company’s executive compensation program. The New Agreement provides for a term ending December 31, 2021, with such term extending automatically for successive one year terms thereafter unless either Dr. Durrant or the Company gives six months prior notice of non-renewal. Under the New Agreement, Dr. Durrant is entitled to receive certain benefits upon termination of employment under certain circumstances. If the Company terminates Dr. Durrant’s employment for any reason other than “Cause”, or if Dr. Durrant resigns for “Good Reason” (each as such term is defined in the New Agreement), Dr. Durrant will receive a lump sum payment equal to the sum of (i) his then-current annual salary and (ii) the amount of the annual bonus earned by Dr. Durrant for the year prior to the year of termination. The New Agreement additionally provides that if Dr. Durrant resigns for Good Reason or the Company terminates his employment other than for Cause within the three month period prior to or the two year period following a change in control (as such term is defined in the New Agreement), the Company must pay or cause its successor to pay Dr. Durrant a lump sum cash payment equal to two times (a) his annual salary plus (b) the aggregate bonus received by Dr. Durrant for the year immediately preceding the change in control. In addition, upon such a resignation or termination, Dr. Durrant will also be entitled to be reimbursed for certain monthly health plan continuation premiums for up to 18 months, and all outstanding stock options held by Dr. Durrant will immediately vest and become exercisable. On November 3, 2020, the Company entered into a License Agreement (the “License Agreement”) with KPM Tech Co., Ltd. (“KPM Tech”) and its affiliate, Telcon RF Pharmaceutical, Inc. (together with KPM Tech, the “Licensee”). Pursuant to the License Agreement, among other things, the Company granted the Licensee a license under certain patents and other intellectual property to develop and commercialize the Company’s lead product candidate, lenzilumab, for treatment of COVID-19 pneumonia, in South Korea and the Philippines, subject to certain reservations and limitations. The Licensee will be responsible for gaining regulatory approval for, and subsequent commercialization of, lenzilumab in those territories. As consideration for the license, the Licensee has agreed to pay the Company (i) an up-front license fee of $6.0 million, payable promptly following the execution of the License Agreement, (ii) up to an aggregate of $14.0 million in two payments based on achievement by the Company of two specified milestones in the US, and (iii) subsequent to the receipt by the Licensee of the requisite regulatory approvals, double-digit royalties on the net sales of lenzilumab in South Korea and the Philippines. The Licensee has agreed to certain development and commercial performance obligations. It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost plus basis from an existing or future manufacturer. The Licensee has agreed to certain minimum purchases of lenzilumab on an annual basis. On November 5 Pursuant to the CRADA, the Company will be provided access to a full-scale, integrated team of OWS manufacturing, and regulatory subject matter experts, leading decision makers and statistical support in anticipation of applying for EUA and subsequently a Biologics License Application (“BLA”), for lenzilumab as a potential treatment for COVID-19. The CRADA also provides that OWS regulatory experts will work with the Company on U.S. Food and Drug Administration (FDA) communications, meetings and regulatory filings. The CRADA aims to support the ongoing lenzilumab Phase 3 clinical trials, focusing on efficiently generating an EUA and BLA submission. In addition to providing access under EUA, a goal of the CRADA is to ensure lenzilumab receives the benefits provided by Public Law 115-92.

Potentially Dilutive Securiti_2

Potentially Dilutive Securities (Tables)	9 Months Ended
	Sep. 30, 2020
Potentially Dilutive Securities Tables
Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Common Share	The following outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share: As of September 30, 2020 2019 Options to purchase common stock 3,528,642 3,027,875 Warrants to purchase common stock 76,238 66,239 3,604,880 3,094,114

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Summary of stock option activity	A summary of stock option activity for the nine months ended September 30, 2020 under all the Company’s options plans is as follows: Options Weighted Average Outstanding at January 1, 2020 3,176,336 $ 4.73 Granted 781,657 6.59 Exercised (429,330 ) (3.55 ) Cancelled (expired) (21 ) (58.40 ) Outstanding at September 30, 2020 3,528,642 $ 5.30
Schedule of fair value-based measurement of stock options granted under the entity's stock plans estimated using Black-Scholes model	The Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption terms for the nine months ended : Nine Months Ended September 30, 2020 Exercise price $1.90 - $10.64 Market value $1.90 - $10.64 Expected term 5 - 6 years Expected volatility 94.6% - 103.7% Risk-free interest rate 0.28% - 1.57% Expected dividend yield - %
Schedule of total stock-based compensation expense recognized	The Company recorded stock-based compensation expense in the Condensed Consolidated Statements of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 General and administrative $ 909 $ 419 $ 1,415 $ 1,813 Research and development 103 $ 32 219 64 Total stock-based compensation $ 1,012 $ 451 $ 1,634 $ 1,877

Nature of Operations (Details)

Nature of Operations (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 11, 2020	Jul. 27, 2020	Dec. 31, 2019
Reverse stock split	1-for-5
Common stock, shares authorized	225,000,000	225,000,000		225,000,000
Common stock, shares outstanding	51,616,508			22,806,890
2020 Equity Plan [Member]
Shares available for future grant	7,000,000	7,000,000	7,000,000
Minimum [Member]
Common stock, shares outstanding		42,200,000
Maximum [Member]
Common stock, shares outstanding		210,900,000

Potentially Dilutive Securiti_3

Potentially Dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	3,604,880	3,094,114
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	3,528,642	3,027,875
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	76,238	66,239

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)

Apr. 03, 2020

Jul. 02, 2019

Apr. 30, 2020

Jun. 28, 2019

May 30, 2019

Sep. 19, 2018

Sep. 30, 2020

Sep. 30, 2019

Aug. 31, 2018

Jun. 30, 2019

Jun. 28, 2019

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2019

Nov. 12, 2019

Apr. 23, 2019

Jun. 30, 2016

Debt Instrument [Line Items]

Proceeds from advance notes

$ 900,000

Percentage of accrued interest

7.00%

Common stock conversion price

$ 2.25

Intrinsic value of this beneficial conversion feature

$ 143,000

Proceeds from convertible debt

$ 467,000

$ 1,275,000

Issuance of common stock upon note conversions shares

435,924

Interest expense

$ 3,000

$ 343,000

1,336,000

$ 1,003,000

Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 4,300,000

Issuance of common stock upon note conversions shares

2,397,915

Convertible Promissory Note [Member] | Cheval Holdings [Member]

Debt Instrument [Line Items]

Issuance of common stock upon note conversions shares

316,666

Advance Notes [Member]

Debt Instrument [Line Items]

Proceeds from advance notes

1,700,000

2019 Bridge Notes [Member]

Debt Instrument [Line Items]

Accrued interest

0

66,000

Debt instrument amount

$ 1,700,000

$ 1,700,000

Proceeds from advance notes

$ 750,000

2019 Bridge Notes [Member] | June Bridge Notes [Member]

Debt Instrument [Line Items]

Interest rate

7.00%

7.00%

Proceeds from advance notes

3,000,000

Maturity Date

Dec. 31, 2020

2019 Bridge Notes [Member] | November Bridge Notes [Member]

Debt Instrument [Line Items]

Interest rate

7.00%

Debt instrument amount

$ 350,000

$ 350,000

Proceeds from advance notes

$ 3,000,000

Maturity Date

Dec. 31, 2020

2019 Bridge Notes [Member] | November Bridge Notes [Member] | Cheval Holdings [Member]

Debt Instrument [Line Items]

Debt instrument amount

100,000

250,000

2019 Bridge Notes [Member] | November Bridge Notes [Member] | Cameron Durrant [Member]

Debt Instrument [Line Items]

Debt instrument amount

$ 100,000

2019 Bridge Notes [Member] | November Bridge Notes [Member] | Nomis Bay [Member]

Debt Instrument [Line Items]

Debt instrument amount

$ 250,000

2019 Bridge Notes [Member] | April Bridge Notes [Member]

Debt Instrument [Line Items]

Interest rate

7.00%

Proceeds from advance notes

$ 10,000,000

Maturity Date

Dec. 31, 2020

2019 Bridge Notes [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Proceeds from advance notes

$ 950,000

2019 Bridge Notes [Member] | Nomis Bay LTD [Member]

Debt Instrument [Line Items]

Debt instrument amount

$ 750,000

750,000

2019 Bridge Notes [Member] | Cameron Durrant [Member]

Debt Instrument [Line Items]

Debt instrument amount

750,000

750,000

2019 Bridge Notes [Member] | Chief Executive Officer [Member]

Debt Instrument [Line Items]

Debt instrument amount

$ 200,000

$ 200,000

Black Horse Capital, L.P [Member] | Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Term loan interest rate

7.00%

Debt instrument amount

$ 2,500,000

2018 Convertible Notes Payable [Member] | Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Accrued interest

$ 200,000

Interest expense

0

$ 817,000

2018 Convertible Notes Payable [Member] | Non Qualified Financing [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 2.25

Proceeds from convertible debt

$ 10,000,000

2018 Convertible Notes Payable [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 2.25

Intrinsic value of this beneficial conversion feature

$ 1,800,000

2019 Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Debt instrument amount

$ 1,300,000

Percentage of accrued interest

7.50%

2019 Convertible Notes Payable [Member] | Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Accrued interest

100,000

Interest expense

0

$ 219,000

2019 Convertible Notes Payable [Member] | Non Qualified Financing [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 6.25

Proceeds from convertible debt

$ 10,000,000

2019 Convertible Notes Payable [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 6.25

Intrinsic value of this beneficial conversion feature

$ 1,800,000

2018 Notes and 2019 Notes Payable [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Interest expense

$ 0

$ 785,000

2018 Convertible Notes Payable Contingent Beneficial Conversion Features [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 2.25

2019 Convertible Notes Payable Contingent Beneficial Conversion Features [Member] | Advance Notes [Member]

Debt Instrument [Line Items]

Common stock conversion price

$ 6.25

2020 Convertible Redeemable Notes [Member]

Debt Instrument [Line Items]

Interest rate

0.70%

0.70%

Debt discount

$ 0

$ 52,000

Proceeds from convertible debt

518,333

Interest expense

0

165,000

Fair value of convertible notes

$ 0

0

2020 Convertible Redeemable Notes [Member] | One Convertible Redeemable Promissory notes [Member]

Debt Instrument [Line Items]

Debt discount amortization

$ 33,000

Maturity Date

Mar. 13, 2021

2020 Convertible Redeemable Notes [Member] | Two Convertible Redeemable Promissory notes [Member]

Debt Instrument [Line Items]

Debt discount amortization

$ 18,833

Maturity Date

Mar. 19, 2021

Notes Payable To Vendors [Member]

Debt Instrument [Line Items]

Interest rate

10.00%

Notes payable to vendors

$ 1,200,000

Accrued interest

$ 300,000

Maturity Date

Jul. 31, 2020

Notes Payable To Vendors [Member] | 2019 Bridge Notes [Member]

Debt Instrument [Line Items]

Accrued interest

$ 1,100,000

Debt instrument amount

$ 500,000

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Sep. 17, 2020	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 11, 2020	Jul. 27, 2020	Dec. 31, 2019	Nov. 08, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split			1-for-5
Common stock, shares outstanding			51,616,508				22,806,890
Common stock, shares authorized			225,000,000		225,000,000		225,000,000
Weighted average fair value of options granted			$ 5.13
Common stock, par value			$ 0.001				$ 0.001
Common share issued			51,616,508				22,806,890
Total proceeds			$ 139,760
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding					42,200,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding					210,900,000
Equity Incentive Plan Twenty Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period expiration			10 years
Equity Incentive Plan Twenty Twelve [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Equity Incentive Plan Twenty Twelve [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
2020 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant			7,000,000		7,000,000	7,000,000
Percentage of outstanding shares approved equity plan						63.00%
Lincoln Park Capital Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value								$ 0.001
Value of right to sell number of shares								$ 20,000
Common share issued		140,000						141,318
Total proceeds		$ 300
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value			$ 4.35
Total proceeds			$ 71,800
Company issued shares			16,505,743
2020 Underwritten Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued in public offering	9,200,000
Proceeds from public offering	$ 78,200,000
2020 Underwritten Public Offering [Member] | J.P. Morgan Securities LLC and Jefferies LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock	1,200,000
Shares issued in public offering	8,000,000

Stockholders' Equity (Stock Opt

Stockholders' Equity (Stock Option Activity) (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Options
Balance at the beginning of the period (in shares) | shares	3,176,336
Options granted (in shares) | shares	781,657
Options exercised (in shares) | shares	(429,330)
Options Cancelled (expired) (in shares) | shares	(21)
Balance at the end of the period (in shares) | shares	3,528,642
Weighted Average Exercise Price (Per Share)
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 4.73
Options granted (in dollars per share) | $ / shares	6.59
Options Exercised (in dollars per share) | $ / shares	(3.55)
Options Cancelled (expired) (in dollars per share) | $ / shares	(58.40)
Balance at the ending of the period (in dollars per share) | $ / shares	$ 5.30

Stockholders' Equity (Weighted-

Stockholders' Equity (Weighted-Average Assumption) (Details)	9 Months Ended
	Sep. 30, 2020$ / shares
Expected dividend yield	0.00%
Minimum [Member]
Exercise price	$ 1.90
Market value	$ 1.90
Expected term	5 years
Expected volatility	94.60%
Risk-free interest rate	0.28%
Maximum [Member]
Exercise price	$ 10.64
Market value	$ 10.64
Expected term	6 years
Expected volatility	103.70%
Risk-free interest rate	1.57%

Stockholders' Equity (Stock-Bas

Stockholders' Equity (Stock-Based Compensation Expense Recognized) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 1,012	$ 451	$ 1,634	$ 1,877
Unrecognized compensation expense	3,800		$ 3,800
Weighted average period for recognition			2 years 4 months 24 days
Weighted average fair value of options granted			$ 5.13
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	909	419	$ 1,415	1,813
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 103	$ 32	$ 219	$ 64

License and Collaboration Agr_2

License and Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended
	Jul. 19, 2019	May 30, 2019	Sep. 30, 2020	Sep. 30, 2020
Mayo Agreement [Member]
Amount paid in license agreement				$ 200
Zurich Agreement [Member]
Amount paid in license agreement	$ 100
Zurich Agreement [Member] | Research And Development Expense [Member]
Amount paid in license agreement				$ 100
Kite Agreement [Member]
Amount paid in license agreement		$ 8,000
Kite Agreement [Member] | Research And Development Expense [Member]
Amount paid in license agreement			$ 2,000

Savant Arrangements (Details)

Savant Arrangements (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Jun. 30, 2016	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2017
Aggregate cost overages					$ 4,100	$ 3,400
Net of duductible						500
Due to Savant		$ 2,000		$ 2,000	$ 2,100	2,000
Savant Neglected Diseases, LLC [Member]
Number of shares called by warrant	40,000		20,000
Exercise price of warrant	$ 11.25		$ 11.25
Exercise period of warrant	5 years
Due from Savant						$ 1,400
Common stock pursuant to net exercise		10,909

Litigation (Details)

Litigation (Details) - USD ($) $ in Thousands	1 Months Ended
	Jun. 19, 2020	Jun. 30, 2017	Oct. 07, 2020	Jun. 30, 2020
Private Placement [Member]
Amount sought under alledges	$ 4,000
Savant Neglected Diseases, LLC [Member]
Aggregate cost		$ 3,400
Deductible		500
Offset payment due		2,000
Amount owed		$ 1,400
Warrants exercised cashless				20,000
Shares issued				10,909
Savant Neglected Diseases, LLC [Member] | Subsequent Event [Member] | Insufficient under warrant [Member]
Shares issued			10,909
Savant Neglected Diseases, LLC [Member] | Subsequent Event [Member] | Breach of contract related to exercise of warrants [Member]
Warrants exercised cashless			20,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Nov. 03, 2020	Oct. 05, 2020
License Agreement with KPM Tech Co., Ltd [Member]
Subsequent Event [Line Items]
License fee	$ 6,000,000
Aggregate payments for license agreement	$ 14,000,000
License Period	7 years 6 months
Dr. Durrant [Member]
Subsequent Event [Line Items]
Bonus		$ 1,512,000
Percentage of bonus paid in cash		50.00%
Percentage of bonus paid in stock options		50.00%
Annual base salary		$ 600,000
Percentage of annual bonus targeted		60.00%